Starbucks stock trades in the mid-$80s (Nasdaq: SBUX) after a recent bounce; it remains down about 9–10% over the past year ts2.tech simplywall.st. CEO
Stock Performance and Recent Moves Ford’s stock has been on a roller-coaster. After trading near 52-week highs around $12 in late summer, shares tanked
Recent Stock Performance Exxon Mobil’s stock has been relatively steady in mid-October. After closing at about $112.24 on Oct. 17 stockanalysis.com, the shares are near
IBIT Price and Recent Performance BlackRock’s iShares Bitcoin Trust ETF (IBIT) has ridden Bitcoin’s rollercoaster in October. The fund’s share price currently sits around
GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test news.samsung.com tradingview.com. GRAIL, Inc. is
Bitfarms Stock Volatile as it Hits $5 Amid Crypto Surge It’s been a whirlwind week for Bitfarms stock. The price seesawed dramatically, reflecting both
Intel Stock Price & Recent Performance Intel’s share price has been on a roller coaster in recent days, reflecting excitement about its prospects tempered
Apple’s stock is trading near record levels as of mid-October 2025. Last week (Oct. 13–17), AAPL shares oscillated in the $247–$252 range, closing at $252.29
Sources: Ford Motor Co. stock price data from Yahoo/Google Finance; Reuters; TechStock² (TS2.tech) financial news reuters.com ts2.tech ts2.tech ts2.tech; company statements.
SPCE’s October Volatility: Surge and Selloff In mid-October 2025, Virgin Galactic’s stock was a top mover in the market. After languishing in the low-$3
Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range
Indonesia’s abrupt pivot to Chinese fighters has captured global attention. Defense analysts say it underscores Jakarta’s insistence on strategic autonomy. “Foreign actors can spread
Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early
Debt Restructure Sparks Stock Crash Beyond Meat’s brand remains visible to consumers, but behind the scenes its finances are in crisis. In mid-October 2025
In summary, Gilead’s share price has rallied on a wave of HIV-related breakthroughs, pipeline achievements, and upbeat guidance. With third-quarter results due Oct. 30,